These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use. Lévy E; Margolese HC; Annable L; Chouinard G Can J Psychiatry; 2004 Jun; 49(6):398-402. PubMed ID: 15283536 [TBL] [Abstract][Full Text] [Related]
23. Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status. Chemerinski E; Reichenberg A; Kirkpatrick B; Bowie CR; Harvey PD Schizophr Res; 2006 Jul; 85(1-3):12-9. PubMed ID: 16624531 [TBL] [Abstract][Full Text] [Related]
24. Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study. Cuesta MJ; Sánchez-Torres AM; de Jalón EG; Campos MS; Ibáñez B; Moreno-Izco L; Peralta V Schizophr Bull; 2014 Sep; 40(5):1164-73. PubMed ID: 24072809 [TBL] [Abstract][Full Text] [Related]
26. Cognitive impairment and functional status in elderly institutionalized patients with schizophrenia. Kurtz MM; Moberg PJ; Mozley LH; Hickey T; Arnold SE; Bilker WB; Gur RE Int J Geriatr Psychiatry; 2001 Jun; 16(6):631-8. PubMed ID: 11424173 [TBL] [Abstract][Full Text] [Related]
27. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Kinon BJ; Jeste DV; Kollack-Walker S; Stauffer V; Liu-Seifert H Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):985-96. PubMed ID: 15380859 [TBL] [Abstract][Full Text] [Related]
28. Cognitive impairment and enduring negative symptoms: a comparative study of geriatric and nongeriatric schizophrenia patients. Putnam KM; Harvey PD Schizophr Bull; 2000; 26(4):867-78. PubMed ID: 11087019 [TBL] [Abstract][Full Text] [Related]
29. Association of altered CuZn superoxide dismutase and cognitive impairment in schizophrenia patients with tardive dyskinesia. Wu JQ; Chen DC; Tan YL; Tan S; Wang Z; Yang F; Soares JC; Zhang XY J Psychiatr Res; 2014 Nov; 58():167-74. PubMed ID: 25151339 [TBL] [Abstract][Full Text] [Related]
30. Gait and posture impairment, parkinsonism and cognitive decline in older people. Camicioli R; Wang Y; Powell C; Mitnitski A; Rockwood K J Neural Transm (Vienna); 2007; 114(10):1355-61. PubMed ID: 17641815 [TBL] [Abstract][Full Text] [Related]
31. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. Dean CE; Kuskowski MA; Caligiuri MP J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811 [TBL] [Abstract][Full Text] [Related]
32. "Positive" and "negative" movement disorders in schizophrenia. Sandyk R; Kay SR Int J Neurosci; 1992 Oct; 66(3-4):143-51. PubMed ID: 1305614 [TBL] [Abstract][Full Text] [Related]
34. Effects of trihexyphenidyl on MMSE and CAMCOG scores of medicated elderly patients with schizophrenia. Heinik J Int Psychogeriatr; 1998 Mar; 10(1):103-8. PubMed ID: 9629529 [TBL] [Abstract][Full Text] [Related]
36. Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. Harvey PD; Leff J; Trieman N; Anderson J; Davidson M Int J Geriatr Psychiatry; 1997 Oct; 12(10):1001-7. PubMed ID: 9395932 [TBL] [Abstract][Full Text] [Related]
37. Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism: The Rotterdam Study. Darweesh SKL; Wolters FJ; Postuma RB; Stricker BH; Hofman A; Koudstaal PJ; Ikram MK; Ikram MA JAMA Neurol; 2017 Dec; 74(12):1431-1438. PubMed ID: 28973176 [TBL] [Abstract][Full Text] [Related]